Independent, AI-assisted research · Affiliate disclosure
HBOT Finder
article

Hyperbaric Oxygen Therapy for Anti-Aging and Longevity

Updated Jun 2026

March 23, 2026 · 6 min read

Quick Answer

  • A 2020 Tel Aviv University trial found 60 HBOT sessions increased telomere length up to 38% and reduced senescent cell counts up to 37% in healthy adults aged 64+ per [Hachmo et al., Aging 2020](https://www.aging-us.com/article/202188/text).
  • Anti-aging is NOT a cleared indication on the [UHMS 15th Edition Indications (2025)](https://www.uhms.org/resources/hbo-indications.html); the [FDA Safety Communication (2021, reaffirmed 2024)](https://www.fda.gov/consumers/consumer-updates/hyperbaric-oxygen-therapy-get-facts) explicitly warns against off-label longevity marketing.
  • The published evidence is one site, n=35, no independent replication. Honest read: promising, early, not yet standard of care.
  • Cash cost runs $6,000-$15,000 for the 60-session protocol; not covered by Medicare under [CMS NCD 20.29](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=12) or commercial plans.

The Tel Aviv telomere study put HBOT on the longevity map. Since then biohackers have spent significant cash chasing the same protocol, and clinics have built marketing around it.

The science is genuinely interesting. The regulatory and replication picture is genuinely thin. This article walks through both.

The Aging Biology HBOT Targets

Biological aging has many hallmarks per López-Otín et al., Cell 2023. HBOT research has focused on two.

Telomere Shortening

Telomeres are protective caps on the ends of chromosomes. They shorten with each cell division.

Critically short telomeres trigger replicative senescence. The link between short telomeres and age-related disease earned Blackburn, Greider, and Szostak the Nobel Prize in 2009.

Normal shortening runs roughly 20-40 base pairs per year in adults per the NIH telomere biology reference (2024).

Cellular Senescence

Senescent cells stop dividing but resist apoptosis. They secrete inflammatory molecules — the senescence-associated secretory phenotype, or SASP — that damage neighbors.

Clearing senescent cells (senolytics) is one of the most active longevity research areas. The first human senolytic trial was Justice et al., EBioMedicine 2019.

The Tel Aviv Telomere Study

The cornerstone of HBOT longevity research is Hachmo et al., Aging 2020, run by Tel Aviv University and Shamir Medical Center. See detailed Shamir long-COVID RCT analysis for the full Shamir-RCT methodology analysis.

Design

  • Participants: 35 healthy adults aged 64 and older
  • Protocol: 60 sessions over 90 days, 5 sessions per week
  • Pressure: 2.0 ATA on 100% oxygen
  • Session length: 90 minutes including intermittent air breaks
  • Measurements: Telomere length and senescent cell counts in isolated peripheral blood mononuclear cells

Results

  • Telomere length increased up to 38% in B cells and 20% in T helper cells
  • Senescent T cells decreased up to 37%
  • Changes were equivalent to reversing roughly 25 years of telomere attrition in some cell populations per the authors' analysis

The Hyperoxic-Hypoxic Paradox

The proposed mechanism involves intermittent oxygen swings.

  1. During HBOT, tissue oxygen rises sharply
  2. When the chamber depressurizes, tissues experience a relative hypoxic signal
  3. The fluctuation activates HIF-1 alpha pathways and downstream telomerase and autophagy

Air breaks during sessions amplify this by creating multiple hyperoxic-hypoxic cycles per session. Hadanny and Efrati, Biomolecules 2020 detail the mechanism.

The 2024 Follow-Up

A follow-up published in Scientific Reports 2024 tracked participants more than one year post-treatment.

  • Telomere length remained elevated versus pre-treatment baseline
  • Senescent cell reductions were maintained
  • No delayed adverse effects reported

This addresses the durability question. It does not address replication.

Other Anti-Aging Mechanisms

Stem Cell Mobilization

HBOT increases circulating CD34+ stem cells. Thom et al., American Journal of Physiology 2006 documented an eightfold increase after 20 sessions.

Stem cell decline is one of the 12 hallmarks of aging per López-Otín 2023.

Cerebral Blood Flow

A separate Shamir trial found HBOT increased cerebral blood flow and cognitive performance in older adults per Hadanny et al., Aging 2020. Sample size was small (63 participants) and the trial was not sham-controlled.

Inflammation

Chronic low-grade inflammation — "inflammaging" — is a recognized aging driver per Franceschi et al., Nature Reviews Endocrinology 2018.

HBOT lowers circulating CRP and IL-6 in some patient populations, though the magnitude in healthy aging adults is less well characterized.

What We Don't Know

The honest gap list.

  • One research group: The telomere findings have not been independently replicated by a different team
  • Small samples: n=35 is enough to detect a signal, not enough to establish population-level effects
  • No healthspan data: We know biomarkers shifted; we don't know whether participants lived longer or healthier
  • Healthy adults only: The Tel Aviv cohort was healthy; effects in adults with chronic disease are unknown
  • Optimal dose unknown: 60 sessions is what was studied. Whether 30 or 40 would work or whether boosters are needed is unknown
  • No head-to-head: HBOT has never been compared head-to-head with exercise, caloric restriction, or senolytics

Practical Considerations

Protocol That Matches the Evidence

  • Sessions: 60 total
  • Frequency: 5 days per week
  • Duration: 90 minutes per session
  • Pressure: 2.0 ATA
  • Oxygen: 100% medical grade
  • Air breaks: Intermittent — these are not optional in the published protocol
  • Total timeline: roughly 12 weeks

Cost

  • Private clinics: $100-$250 per session, or $6,000-$15,000 for the protocol
  • Hospital-based: Rarely offered for anti-aging; if available, $350-$600 per session
  • Insurance: Denied. Anti-aging is not on CMS NCD 20.29 and not on the UHMS 15th Edition list (2025)
  • HSA/FSA: Generally not eligible without a treating physician's documentation of a covered medical condition

Finding a Provider

  • Hard-shell chamber capable of 2.0 ATA on 100% oxygen — soft-shell chambers at 1.3 ATA do not replicate the trial conditions
  • Familiarity with intermittent air-break protocols
  • Physician oversight including baseline screening per UHMS Clinical Hyperbaric Facility Accreditation Manual (2023)
  • Willingness to discuss what the evidence does and doesn't say

Measuring Results

If you're paying for an off-label longevity protocol, measure something.

  • Telomere length (TeloYears, Life Length) before and 1-3 months post
  • Epigenetic age (TruAge, GrimAge)
  • Inflammatory markers: hsCRP, IL-6
  • Functional measures: VO2 max, grip strength, neuropsych testing

HBOT vs Other Longevity Interventions

InterventionEvidence LevelCostTimeInsurance
Regular exerciseVery strongLowOngoingN/A
Caloric restrictionModerate-strongLowOngoingN/A
HBOT (60 sessions)Early (one site, n=35)$6,000-$15,00012 weeksNo
RapamycinModerate (mostly animal)$100-$200/moOngoingNo
NAD+ precursorsWeak-moderate$50-$150/moOngoingNo
Senolytics (D+Q)Moderate (early clinical)$100-$500/coursePeriodicNo
Metformin (TAME)Moderate (ongoing)$10-$30/moOngoingSometimes

Frequently Asked Questions

Is HBOT FDA-cleared for anti-aging?

No. The FDA Safety Communication (2021, reaffirmed 2024) explicitly states HBOT is not cleared for anti-aging, longevity, or any wellness use, and warns consumers about clinics marketing off-label. The 14 cleared indications cover acute and chronic medical conditions, not aging itself.

Does mild HBOT at 1.3 ATA produce the same anti-aging effects?

The Tel Aviv telomere data came from hard-shell chambers at 2.0 ATA on 100% oxygen with intermittent air breaks. Soft-shell chambers at 1.3 ATA on ambient or concentrated air produce dramatically lower tissue oxygen and cannot replicate the hyperoxic-hypoxic paradox described in Hadanny and Efrati, Biomolecules 2020. No published data show comparable telomere or senescent cell effects from mild HBOT.

What age should I start?

The trial enrolled adults 64 and older. The underlying biology (telomere attrition, senescent cell accumulation) starts decades earlier per López-Otín et al., Cell 2023. There is no published evidence in younger populations. The optimal starting age has not been established.

Do I need to repeat the protocol?

The 1-year follow-up showed effects persisted. Whether they persist at 2, 5, or 10 years is unknown. Some clinicians recommend annual booster courses based on judgment, not published evidence.

How does HBOT compare to exercise?

Exercise has decades of evidence for cardiovascular, cognitive, muscular, skeletal, and metabolic benefit, plus modest telomere-protective effects per Werner et al., European Heart Journal 2019. HBOT should be viewed as a possible complement, not a replacement.

Related Reading

Find HBOT Centers Near You

Browse our directory of UHMS-accredited HBOT centers to find facilities capable of running 2.0 ATA protocols under physician supervision.


-- The HBOT Finder Team

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. HBOT for anti-aging is an off-label use not cleared by the FDA and not covered by insurance. Discuss any longevity protocol with a qualified physician.

Editorial Disclosure: HBOT Finder maintains editorial independence. We do not accept paid placements in our clinic directory.

On Google

Get our answers in your Google results.

Add HBOT Finder as a preferred source and Google will surface our hyperbaric coverage more often — in Top Stories and AI answers, marked with a preferred badge. One tap, free, undo anytime.

Add us as a preferred source

Opens Google's source preferences for hyperbaricfinder.com. No sign-up with us — it's a Google setting.

Find a Clinic

Why are you considering hyperbaric oxygen therapy?

Related Articles

Stay in the loop

Get the latest articles delivered to your inbox.